Related Experiment Video
Updated: Oct 7, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Methotrexate-induced liver fibrosis in chronic inflammatory diseases: A cross-sectional study in the Tunisian
Sarra Laabidi1, Amal Hajlaoui1, Maissa Abbes2
1Department of Gastro Enterology, Rabta Hospital, Tunis, Tunisia; Faculty of Medicine of Tunis, Tunis El Manar university, Tunisia.
Background And Study Aims:
Methotrexate (MTX) is an immunosuppressive drug used to treat various chronic inflammatory diseases. While its association with liver fibrosis is concerning, several associated factors appear to play a major role. This study aimed to assess the frequency of fibrosis in MTX-treated patients and identifies its associated factors.
Patients And Methods:
A descriptive cross-sectional study was conducted including patients with chronic inflammatory diseases who had been on MTX for at least 6 months. Liver fibrosis was assessed using transient elastography. A comparative analysis was performed between patients with and without fibrosis, defined by liver stiffness >7 kPa.
Results:
A total of 160 patients were included (rheumatoid arthritis (45%), psoriasis (19%), Crohn's disease (19%)), with a mean age of 53.8 years and sex-ratio F/M = 2.1. The mean duration of MTX treatment was 38 months, with an average cumulative dose of 2.340 mg. Liver fibrosis, was detected in 11.9% of patients. In a multivariate study, independent factors associated with liver fibrosis included age > 59 years (OR = 18), alcohol consumption >15.17 g/day (OR = 4.2), metabolic syndrome (OR = 9), and obesity (OR = 18).
Conclusion:
Liver fibrosis under MTX was observed in 11.9% of patients, influenced by advanced age, alcohol consumption, metabolic syndrome, and obesity. These findings highlight the need for targeted monitoring to prevent complications.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Therapeutic Drug Monitoring: Affecting Factors